Evidence map›Paper›PMID 42745361›Full record

ArticlePharmacology research & perspectives2026

(+)-Trans-Cannabidiol Is an Agonist at Human CB

Pedro Bans Burtchaell, Marina Junqueira Santiago, Chenxi Wang, Mehdi Hagdoost, Evie J M Clay, Dani Mohnot, Mark Connor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pedro Bans BurtchaellSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland.
Marina Junqueira SantiagoMacquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9388-8309
Chenxi WangSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland.
Mehdi HagdoostNalu Bio, San Francisco, California, USA.
Evie J M ClaySchool of Natural Sciences, Macquarie University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0009-0003-1108-1192
Dani MohnotMacquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia.ORCID https://orcid.org/0009-0003-7780-3012
Mark ConnorMacquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia.ORCID https://orcid.org/0000-0003-2538-2001

Funding

Australian Research Council IC210100040Office of the Chief Scientist and Engineer, Investment NSW
6 · The paper itself

Abstract

(-)-trans-Cannabidiol ((-)-CBD) is a principal phytocannabinoid from Cannabis sativa. (-)-CBD has complex pharmacology but is a relatively weak inhibitor of CB

Indexed as

CannabidiolCannabinoid Receptor AgonistsReceptor, Cannabinoid, CB2AnimalsCell LineCyclohexanolsDose-Response Relationship, DrugHumansIndolesMembrane PotentialsMolecular Docking SimulationReceptor, Cannabinoid, CB1Stereoisomerism3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolCannabidiolCannabinoid Receptor AgonistsCNR2 protein, humanCyclohexanolsIndolesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2agonismcannabinoidchiralityG protein coupled receptor

Identifiers

PMID42745361
PMCPMC13578601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.